MicroRNAs as potential target in human bone and soft tissue sarcoma therapeutics

Varshney, Jyotika; Subramanian, Subbaya

doi:10.3389/fmolb.2015.00031

Cited by 34 publications

(34 citation statements)

References 113 publications

(135 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…miRs are gene regulation factors involved in numerous pathophysiological processes, including the proliferation, invasion and metastasis of tumor cells, hypertension, diabetes and atherosclerosis (21,22). Studies are currently investigating the functions of an increasing number of miRs.…”

Section: Discussionmentioning

confidence: 99%

MicroRNA-17 downregulates expression of the PTEN gene to promote the occurrence and development of adenomyosis

2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. The aim of the current study was to evaluate the expression of microRNA (miR)-17 in the endometrial tissues of patients with adenomyosis (AM) and determine its biological function in the occurrence and development of the disease. A total of 45 fresh endometrial tissues of AM patients and 32 normal endometrial tissues were collected from healthy controls. The expression of miR-17 was evaluated using reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The miR-17-targeting gene phosphatase and tensin homolog (PTEN) was predicted using bioinformatics and its expression was evaluated with RT-qPCR and western blot analysis. Endometrial cells were isolated from patients with AM and healthy controls. They were cultured in vitro and transfected with antagomiR-17 to downregulate miR-17 expression, subsequently cell viability and apoptosis were measured using MTT and flow cytometry. The expression of PTEN and cell cycle-and apoptosis-related proteins were evaluated using western blot analysis. Endometrial cells that stably overexpressed PTEN were screened in vitro by co-culture with G418. A dual-luciferase reporter assay was conducted to verify whether miR-17 was directly bound to PTEN mRNA. The results demonstrated that expression of miR-17 was significantly increased in the endometrial tissues of patients with AM compared with control patients (P<0.05). PTEN mRNA and protein expression were significantly lower in the AM group compared with the control group (P<0.05). When the expression of miR-17 in the cells was downregulated, the expression of PTEN was significantly increased (P<0.05). In addition, expression of Bcl-2 protein was significantly decreased and that of Bax protein significantly increased compared with the negative control (both P<0.05). The expression of cyclins E1 and D1 were also significantly downregulated (P<0.05). When PTEN was overexpressed or miR-17 was downregulated, the viability of endometrial cells significantly decreased and cell apoptosis significantly increased (all P<0.05). A dual-luciferase reporter assay indicated that miR-17 could directly bind to the PTEN mRNA 3'-untranslated region to regulate its expression. Thus the current study indicates that expression of miR-17 was increased in the endometrial tissues of patients with AM and may influence cell apoptosis and cyclin expression through the targeted regulation of PTEN. These results suggest that miR-17 promotes the occurrence and development of AM.

show abstract

Section: Discussionmentioning

confidence: 99%

MicroRNA-17 downregulates expression of the PTEN gene to promote the occurrence and development of adenomyosis

2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…Soft tissue sarcomas (STS) are a group of rare heterogeneous cancers of mesenchymal tissues consisting of more than 50 histological subtypes and account for~1% of all malignant tumors [1]. Regardless of the advancement in understanding of STS, treatment options are stagnant for the past few decades because of their rarity, genetic complexities, and late diagnosis.…”

Section: Introductionmentioning

confidence: 99%

“…In recent years, miRNAs have shown encouraging results as potential biomarkers in many sarcoma types [8,9]. Several studies are being undertaken to target them which is essential for development of enhanced therapies for various human sarcomas [1]. Till date, there are only a handful of miRNAs reported in STS metastasis.…”

Section: Introductionmentioning

confidence: 99%

miR-429 inhibits metastasis by targeting KIAA0101 in Soft Tissue Sarcoma

Samantarrai

Mallick

2017

Experimental Cell Research

View full text Add to dashboard Cite

“…Outra importância está relacionada ao tratamento quimioterápico, sendo que os miRNAs também são utilizados como biomarcadores da resposta ao osteossarcoma. Um exemplo disso é a expressão aumentada de miR-140 e miR-215, que cursa com resistência a vários quimioterápicos, como o metotrexato (VARSHNEY ; SUBRAMANIAN, 2015).…”

Section: Terapias Alternativas -Micrornaunclassified

Agentes Antineoplásicos Para O Tratamento Do Osteossarcoma

Gabriel¹,

Nepomuceno²,

Pimenta³

et al. 2017

Enci Bio

View full text Add to dashboard Cite

RESUMOO osteossarcoma é o tumor ósseo de maior ocorrência, sendo seu estudo importante nas espécies humana e canina. As crianças e jovens são mais frequentemente acometidas, por estarem em uma idade quando ocorre maior crescimento ósseo, sendo que o contrário ocorre nos animais, que são acometidos geralmente com idade avançada entre seis a 10 anos. A etiologia do tumor é desconhecida e as taxas de mortalidade são altas, variando de 40 a 50% para os humanos e chegando até 80% nos animais. O tratamento é baseado na remoção cirúrgica do tumor e quimioterapia, associação esta que permitiu melhora nos resultados dos tratamentos, mas cursa com intensa toxicidade e inúmeros efeitos adversos para os pacientes. Sem melhora significativa nas taxas de cura nos últimos 30 anos, a busca de tratamentos alternativos para o osteossarcoma é necessária para aumentar a expectativa de vida dos pacientes e diminuir a ocorrência de efeitos adversos. PALAVRAS-CHAVE: oncologia comparativa, quimioterapia, toxicidade. ANTINEOPLASTIC AGENTS FOR THE TREATMENT OF OSTEOSARCOMA ABSTRACTOsteosarcoma is the most frequent bone tumor, being important in both medicine and veterinary medicine. Children and youngsters are more frequently affected because they are at an age where there is greater bone growth, whereas the opposite occurs in animals, which are usually affected at an advanced age between 6 and 10 years. The etiology of the tumor is unknown and mortality rates are high, ranging from 40 to 50% for humans and up to 80% in animals. The treatment is based on the surgical removal of the tumor and chemotherapy, an association that allowed improvement in the results of the treatments, but presents with intense toxicity and numerous adverse effects for the patients. Without significant improvement in cure rates over the past 30 years, the search for alternative

show abstract

MicroRNAs as potential target in human bone and soft tissue sarcoma therapeutics

Cited by 34 publications

References 113 publications

MicroRNA-17 downregulates expression of the PTEN gene to promote the occurrence and development of adenomyosis

MicroRNA-17 downregulates expression of the PTEN gene to promote the occurrence and development of adenomyosis

miR-429 inhibits metastasis by targeting KIAA0101 in Soft Tissue Sarcoma

Agentes Antineoplásicos Para O Tratamento Do Osteossarcoma

Contact Info

Product

Resources

About